Dorota Kozielewicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9408215/publications.pdf

Version: 2024-02-01

759233 839539 19 335 12 18 citations h-index g-index papers 19 19 19 407 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland. Journal of Clinical Medicine, 2022, 11, 117.	2.4	18
2	The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland. Environmental Pollution, 2022, 306, 119469.	7. 5	20
3	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. Journal of Clinical Medicine, 2021, 10, 1583.	2.4	21
4	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, 487-496.	0.4	48
5	Impact of Kidney Failure on the Severity of COVID-19. Journal of Clinical Medicine, 2021, 10, 2042.	2.4	13
6	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. Journal of Inflammation Research, 2021, Volume 14, 3359-3366.	3.5	17
7	Convalescent Plasma Transfusion for the Treatment of COVID-19â€"Experience from Poland: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 28.	2.4	23
8	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, .	0.4	6
9	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. Polish Archives of Internal Medicine, 2020, 130, 352-357.	0.4	51
10	Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Polish Archives of Internal Medicine, 2020, 130, 557-558.	0.4	20
11	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. Polish Archives of Internal Medicine, 2020, 130, 915-918.	0.4	30
12	Efficacy and safety of pegylated interferon \hat{l}_{\pm} and ribavirin in patients monoinfected with HCV genotype 4. Przeglad Gastroenterologiczny, 2018, 13, 22-29.	0.7	3
13	Effectiveness and safety of ledipasvir/sofosbuvir $\hat{A}\pm$ ribavirin in the treatment of HCV infection: The real-world HARVEST study. Advances in Medical Sciences, 2017, 62, 387-392.	2.1	23
14	Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin. Przeglad Epidemiologiczny, 2017, 71, 555-569.	0.2	1
15	Prophylaxis of vertical HBV infection. Expert Opinion on Drug Safety, 2016, 15, 1361-1368.	2.4	18
16	Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatology International, 2016, 10, 302-309.	4.2	3
17	The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. PLoS ONE, 2015, 10, e0130899.	2.5	13
18	Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. Neurologia I Neurochirurgia Polska, 2015, 49, 451-455.	1.2	5

#	Article	IF	CITATIONS
19	Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert Opinion on Drug Safety, 2015, 14, 1815-1825.	2.4	2